Duke oncology startup led by former Trimeris CEO raises $4M
Durham, N.C. — Istari Oncology, a North Carolina-based company, raised nearly $4 million in a private stock offering, according to a Securities and Exchange Commission filing.
Istari Oncolgoy filed the Form D on Feb. 13. It did not disclose what it tended to do with the proceeds.
The company began in 2014 as a Duke University start-up and works to cure recurrent glioblastoma [a form of brain cancer]. Executive officers and directors Dani Bolognesi, Henry Friedman and Darell Bigner lead the company.
Bolognesi is the former chief executive officer of Trimeris, which developed AIDS drugs. He is also the director of the Center for AIDS Research at Duke University.
Friedman is a professor of pediatric oncology at Duke while Bigner is a cancer research professor.
Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically after they first sell their securities.
Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism
Please Log In to add a comment.
Latest for Insiders
- CED Life Science Conference to showcase Triangle's remarkable success story
- Exits of Plastina, Lipson are good news for Triangle - Here's why
- Study: 'Tasty' cannabis edibles need better labels for safety
- Report spells out strategy for how NC can cash in on 'data economy'
- Report: NC equity funding drops $400M in '16 yet reach grows
- Despite big changes, Google Fiber says it's 'here to stay in Triangle'
- Duke inventors' kitchen safety recipe: Internet of Things stove control, app raises $175K
- A witness to amazing RDU growth: Jammed LA-to-RDU Sunday night flight
- IBM's top exec defends Trump role in letter to employees
- Inside Offline's big deal with McClatchy: What's next for Raleigh startup, how deal was made